[{"id":"3a8e94f4-0040-4f56-93f4-fd86db056dcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT06879041","created_at":"2025-06-07T14:42:17.891Z","updated_at":"2025-06-07T14:42:17.891Z","phase":"Phase 1","brief_title":"A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT06879041","lead_sponsor":"AstraZeneca","biomarkers":" STEAP1","pipe":"","alterations":" ","tags":["STEAP1"],"overall_status":"Recruiting","enrollment":" Enrollment 134","initiation":"Initiation: 03/10/2025","start_date":" 03/10/2025","primary_txt":" Primary completion: 04/16/2029","primary_completion_date":" 04/16/2029","study_txt":" Completion: 04/16/2029","study_completion_date":" 04/16/2029","last_update_posted":"2025-06-04"},{"id":"cf2cfcd4-c077-4397-9d63-381c2282ddc5","acronym":"TATCIST","url":"https://clinicaltrials.gov/study/NCT05219500","created_at":"2022-02-05T18:28:39.147Z","updated_at":"2025-02-25T15:12:35.305Z","phase":"Phase 2","brief_title":"Targeted Alpha Therapy with 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I\u0026T of Castration-resISTant Prostate Cancer (TATCIST).","source_id_and_acronym":"NCT05219500 - TATCIST","lead_sponsor":"Fusion Pharmaceuticals Inc.","biomarkers":" MSI • BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["MSI • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FPI-2265"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 115","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2025-02-13"},{"id":"e91a001c-1388-4b9d-9fd5-c4bd92315a77","acronym":"","url":"https://clinicaltrials.gov/study/NCT04579523","created_at":"2021-01-18T21:51:25.345Z","updated_at":"2025-02-25T15:18:52.701Z","phase":"Phase 1","brief_title":"²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma","source_id_and_acronym":"NCT04579523","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":" | ","alterations":" Chr del(17p)","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(17p)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2025","start_date":" 05/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-12"},{"id":"2d8fede0-d3af-4a3f-8d61-856862f007e8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03128034","created_at":"2021-01-18T15:24:33.202Z","updated_at":"2025-02-25T16:31:10.471Z","phase":"Phase 1/2","brief_title":"211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia","source_id_and_acronym":"NCT03128034","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus • fludarabine IV • cyclosporin A microemulsion"],"overall_status":"Recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 10/24/2017","start_date":" 10/24/2017","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 03/31/2029","study_completion_date":" 03/31/2029","last_update_posted":"2025-02-07"},{"id":"7c4709ee-03b2-4e5b-b8af-61df0f32ed05","acronym":"NCI-2018-01788","url":"https://clinicaltrials.gov/study/NCT03670966","created_at":"2021-01-18T18:00:29.277Z","updated_at":"2025-02-25T16:44:27.913Z","phase":"Phase 1/2","brief_title":"211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome","source_id_and_acronym":"NCT03670966 - NCI-2018-01788","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/10/2019","start_date":" 07/10/2019","primary_txt":" Primary completion: 06/28/2027","primary_completion_date":" 06/28/2027","study_txt":" Completion: 03/20/2029","study_completion_date":" 03/20/2029","last_update_posted":"2025-02-05"},{"id":"34339220-1770-4108-8649-484d7d43cefa","acronym":"212-Pb-VMT","url":"https://clinicaltrials.gov/study/NCT05636618","created_at":"2022-12-05T15:56:36.062Z","updated_at":"2025-02-25T17:38:15.153Z","phase":"Phase 1/2","brief_title":"Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors","source_id_and_acronym":"NCT05636618 - 212-Pb-VMT","lead_sponsor":"Perspective Therapeutics","biomarkers":" SSTR • CD4 • SSTR2","pipe":" | ","alterations":" SSTR2 expression • SSTR2 positive","tags":["SSTR • CD4 • SSTR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR2 expression • SSTR2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMT-𝛼-NET"],"overall_status":"Recruiting","enrollment":" Enrollment 280","initiation":"Initiation: 09/27/2023","start_date":" 09/27/2023","primary_txt":" Primary completion: 11/26/2029","primary_completion_date":" 11/26/2029","study_txt":" Completion: 12/26/2029","study_completion_date":" 12/26/2029","last_update_posted":"2025-01-29"},{"id":"4baf504a-3428-46d7-aa11-1c6d5b48f340","acronym":"ACTION-1","url":"https://clinicaltrials.gov/study/NCT05477576","created_at":"2022-07-28T14:55:31.876Z","updated_at":"2025-02-25T17:37:59.568Z","phase":"Phase 3","brief_title":"Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","source_id_and_acronym":"NCT05477576 - ACTION-1","lead_sponsor":"RayzeBio, Inc.","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • everolimus • Actinium-225 DOTATATE (RYZ101) • lanreotide prolonged-release subcutaneous • octreotide acetate"],"overall_status":"Recruiting","enrollment":" Enrollment 288","initiation":"Initiation: 03/24/2022","start_date":" 03/24/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 07/01/2028","study_completion_date":" 07/01/2028","last_update_posted":"2025-01-29"},{"id":"2502e95e-e4c1-4a43-8fda-b4937c0e5814","acronym":"","url":"https://clinicaltrials.gov/study/NCT03093428","created_at":"2021-01-29T07:14:23.379Z","updated_at":"2025-02-25T16:05:59.369Z","phase":"Phase 2","brief_title":"Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC","source_id_and_acronym":"NCT03093428","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 06/09/2017","start_date":" 06/09/2017","primary_txt":" Primary completion: 04/09/2020","primary_completion_date":" 04/09/2020","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2025-01-24"},{"id":"7b8a02fc-93ba-4510-a730-5331f3179340","acronym":"","url":"https://clinicaltrials.gov/study/NCT04147819","created_at":"2021-01-18T20:19:04.190Z","updated_at":"2025-02-25T17:11:00.786Z","phase":"Phase 1","brief_title":"A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein","source_id_and_acronym":"NCT04147819","lead_sponsor":"Bayer","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAY2701439 • BAY2701438"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 08/21/2023","primary_completion_date":" 08/21/2023","study_txt":" Completion: 09/26/2023","study_completion_date":" 09/26/2023","last_update_posted":"2024-09-27"},{"id":"3d98dd1f-987f-4c68-94e3-38adc1f3cdfa","acronym":"BAT-RAD","url":"https://clinicaltrials.gov/study/NCT04704505","created_at":"2021-01-19T20:51:15.415Z","updated_at":"2025-02-25T17:24:58.474Z","phase":"Phase 2","brief_title":"Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT04704505 - BAT-RAD","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 04/28/2022","start_date":" 04/28/2022","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2024-06-18"},{"id":"075a5201-e3f8-44b6-8b44-76394d647793","acronym":"ALPHAMEDIX02","url":"https://clinicaltrials.gov/study/NCT05153772","created_at":"2021-12-10T23:53:34.786Z","updated_at":"2025-02-25T13:49:19.721Z","phase":"Phase 2","brief_title":"Targeted Alpha-emitter Therapy of PRRT Naïve and Previous PRRT Neuroendocrine Tumor Patients","source_id_and_acronym":"NCT05153772 - ALPHAMEDIX02","lead_sponsor":"Radiomedix, Inc.","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AlphaMedix (SAR447873)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 12/21/2021","start_date":" 12/21/2021","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-27"},{"id":"076eece4-6905-454a-8a07-8b842556ea06","acronym":"","url":"https://clinicaltrials.gov/study/NCT05595460","created_at":"2022-10-27T15:58:19.568Z","updated_at":"2024-07-02T16:35:01.901Z","phase":"Phase 1","brief_title":"Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC","source_id_and_acronym":"NCT05595460","lead_sponsor":"RayzeBio, Inc.","biomarkers":" PD-L1 • SSTR","pipe":" | ","alterations":" SSTR positive","tags":["PD-L1 • SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • carboplatin • etoposide IV • Actinium-225 DOTATATE (RYZ101)"],"overall_status":"Recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 10/10/2022","start_date":" 10/10/2022","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-05-22"},{"id":"f44f76e4-0ba3-4481-b09e-d12b99a9cec1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05655312","created_at":"2022-12-19T15:59:21.058Z","updated_at":"2024-07-02T16:35:11.693Z","phase":"Phase 1/2","brief_title":"MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma","source_id_and_acronym":"NCT05655312","lead_sponsor":"Perspective Therapeutics","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VMT-01"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2024-04-03"},{"id":"937bec61-abb0-4838-bc7e-ee7138f0f459","acronym":"MED20-165","url":"https://clinicaltrials.gov/study/NCT04512716","created_at":"2021-01-18T21:37:46.095Z","updated_at":"2024-07-02T16:35:15.633Z","phase":"Phase 1","brief_title":"Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04512716 - MED20-165","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD20 • CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iomab-B (I-131-apamistamab) • apamistamab-I-131 (Iomab-ACT) • vadacabtagene leraleucel (JCAR015)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/02/2021","start_date":" 02/02/2021","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-03-08"},{"id":"236caabf-f765-48c1-9acf-9e39f56bd762","acronym":"","url":"https://clinicaltrials.gov/study/NCT04466475","created_at":"2021-01-18T21:27:59.454Z","updated_at":"2024-07-02T16:35:21.519Z","phase":"Phase 1","brief_title":"Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma","source_id_and_acronym":"NCT04466475","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/27/2024","start_date":" 01/27/2024","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-01-31"},{"id":"843d1194-3194-45a2-a9e4-951c039304c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02258451","created_at":"2021-01-18T10:36:32.901Z","updated_at":"2025-02-25T17:07:40.914Z","phase":"Phase 2","brief_title":"Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast Cancer","source_id_and_acronym":"NCT02258451","lead_sponsor":"Bayer","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • exemestane • Xofigo (radium Ra-223 dichloride)"],"overall_status":"Completed","enrollment":" Enrollment 283","initiation":"Initiation: 06/04/2015","start_date":" 06/04/2015","primary_txt":" Primary completion: 01/22/2020","primary_completion_date":" 01/22/2020","study_txt":" Completion: 10/28/2022","study_completion_date":" 10/28/2022","last_update_posted":"2023-11-24"},{"id":"e9dfca51-3f27-45f4-a40b-0bf4c8ceb200","acronym":"","url":"https://clinicaltrials.gov/study/NCT04576871","created_at":"2021-01-18T21:50:54.507Z","updated_at":"2024-07-02T16:35:30.905Z","phase":"Phase 1","brief_title":"Re-treatment 225Ac-J591 for mCRPC","source_id_and_acronym":"NCT04576871","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ac-225 rosopatamab tetraxetan (CONV01-α)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 10/29/2020","start_date":" 10/29/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2023-10-31"},{"id":"5a1c0c02-4fea-4ff0-a201-7fca228602a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05283330","created_at":"2022-03-16T15:54:24.236Z","updated_at":"2024-07-02T16:35:32.524Z","phase":"Phase 1","brief_title":"Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors","source_id_and_acronym":"NCT05283330","lead_sponsor":"Orano Med LLC","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 212Pb-DOTAM-GRPR1"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 12/22/2022","start_date":" 12/22/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2023-10-19"},{"id":"bb9b1fd6-07d2-4950-8e57-40864d118e0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04506567","created_at":"2021-01-18T21:36:26.540Z","updated_at":"2024-07-02T16:35:38.849Z","phase":"Phase 1/2","brief_title":"Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC","source_id_and_acronym":"NCT04506567","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ac-225 rosopatamab tetraxetan (CONV01-α)"],"overall_status":"Recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 08/18/2020","start_date":" 08/18/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2023-08-28"},{"id":"1b36b4ee-0095-44fb-b7a3-0681f98a1eb6","acronym":"ACTION","url":"https://clinicaltrials.gov/study/NCT05567770","created_at":"2022-10-05T12:55:59.042Z","updated_at":"2024-07-02T16:35:39.145Z","phase":"Phase 1","brief_title":"ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer","source_id_and_acronym":"NCT05567770 - ACTION","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ac-225 rosopatamab tetraxetan (CONV01-α)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2023-08-24"},{"id":"f2afbf99-2029-4f29-86c4-41a5cc58b54c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886986","created_at":"2021-05-14T12:52:39.196Z","updated_at":"2024-07-02T16:35:39.458Z","phase":"Phase 1/2","brief_title":"Phase I/II 225Ac-J591 Plus 177Lu-PSMA-I\u0026T for Progressive Metastatic Castration Resistant Prostate Cancer","source_id_and_acronym":"NCT04886986","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" CYP17A1","pipe":"","alterations":" ","tags":["CYP17A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lutetium zadavotide guraxetan (PNT2002) • Ac-225 rosopatamab tetraxetan (CONV01-α)"],"overall_status":"Suspended","enrollment":" Enrollment 48","initiation":"Initiation: 06/30/2021","start_date":" 06/30/2021","primary_txt":" Primary completion: 12/24/2024","primary_completion_date":" 12/24/2024","study_txt":" Completion: 12/27/2027","study_completion_date":" 12/27/2027","last_update_posted":"2023-08-21"},{"id":"8b14bf99-2f4f-4d08-a7e0-83d152f96cb8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03867682","created_at":"2021-01-18T19:04:27.493Z","updated_at":"2024-07-02T16:35:41.038Z","phase":"Phase 1/2","brief_title":"Venetoclax and Lintuzumab-Ac225 in AML Patients","source_id_and_acronym":"NCT03867682","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Erbitux (cetuximab) • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 01/15/2020","start_date":" 01/15/2020","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-08-04"},{"id":"38d70ca6-e60e-428e-839b-b4649d1ec035","acronym":"","url":"https://clinicaltrials.gov/study/NCT03932318","created_at":"2021-01-18T19:22:10.225Z","updated_at":"2024-07-02T16:35:42.415Z","phase":"Phase 1/2","brief_title":"Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients","source_id_and_acronym":"NCT03932318","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • Erbitux (cetuximab) • azacitidine • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-07-20"},{"id":"a7cfcc21-cc8b-4a64-9046-59fd8a1f40d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02575963","created_at":"2021-01-18T12:29:18.783Z","updated_at":"2024-07-02T16:35:42.400Z","phase":"Phase 1/2","brief_title":"Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients","source_id_and_acronym":"NCT02575963","lead_sponsor":"Actinium Pharmaceuticals","biomarkers":" CD33","pipe":" | ","alterations":" CD33 positive","tags":["CD33"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD33 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • cytarabine • Actimab-A (lintuzumab-Ac225)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 10/01/2012","start_date":" 10/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2023-07-20"}]